Provided by Tiger Trade Technology Pte. Ltd.

Apellis Pharmaceuticals Inc.

22.31
-0.2700-1.20%
Post-market: 22.310.00000.00%19:23 EST
Volume:1.88M
Turnover:41.60M
Market Cap:2.82B
PE:62.29
High:22.50
Open:22.46
Low:21.71
Close:22.58
52wk High:30.48
52wk Low:16.10
Shares:126.53M
Float Shares:78.12M
Volume Ratio:0.81
T/O Rate:2.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3581
EPS(LYR):-1.5970
ROE:14.10%
ROA:5.13%
PB:7.04
PE(LYR):-13.97

Loading ...

H.C. Wainwright Sticks to Its Buy Rating for Apellis Pharmaceuticals (APLS)

TIPRANKS
·
Nov 15, 2025

This Undervalued Biotech Might Have Just Proven Its Star Drug's Staying Power

Benzinga_recent_news
·
Nov 13, 2025

Apellis Pharmaceuticals: Safety Profile of Syfovre Through Five Years Remained Consistent With Previously Reported Data

THOMSON REUTERS
·
Nov 12, 2025

Apellis Announces 5-Year Gale Data Showing Syfovre® (Pegcetacoplan Injection) Delayed Progression of Geographic Atrophy by ~1.5 Years

THOMSON REUTERS
·
Nov 12, 2025

Apellis Reports SYFOVRE Delays Geographic Atrophy Progression by 1.5 Years in Five-Year Study

Reuters
·
Nov 12, 2025

Apellis Pharmaceuticals Initiated at Peer Perform by Wolfe Research

Dow Jones
·
Nov 06, 2025

Wolfe Research Initiates Coverage on Apellis Pharmaceuticals With Peer Perform Rating

MT Newswires Live
·
Nov 06, 2025

J.P. Morgan Reaffirms Their Buy Rating on Apellis Pharmaceuticals (APLS)

TIPRANKS
·
Nov 05, 2025

Stock Track | Apellis Pharmaceuticals Plummets 5.05% as Mizuho Slashes Price Target

Stock Track
·
Nov 04, 2025

Stock Track | Apellis Pharmaceuticals Plunges 5% as Mizuho Slashes Price Target

Stock Track
·
Nov 04, 2025

Stock Track | Apellis Pharmaceuticals Plunges 5% Pre-Market as Multiple Analysts Cut Price Targets

Stock Track
·
Oct 31, 2025

Wedbush Lowers Price Target on Apellis Pharmaceuticals to $22 From $23, Keeps Neutral Rating

MT Newswires Live
·
Oct 31, 2025

Apellis Pharmaceuticals (APLS) Receives a Hold from RBC Capital

TIPRANKS
·
Oct 31, 2025

Apellis Pharmaceuticals (APLS) Receives a Hold from Morgan Stanley

TIPRANKS
·
Oct 31, 2025

Apellis Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Oct 31, 2025

Apellis price target lowered to $45 from $57 at H.C. Wainwright

TIPRANKS
·
Oct 31, 2025

U.S. RESEARCH ROUNDUP-Amazon, Apple, Cigna

Reuters
·
Oct 31, 2025

Apellis price target lowered to $27 from $29 at BofA

TIPRANKS
·
Oct 31, 2025

Apellis Pharmaceuticals Down Nearly 24%, on Pace for Largest Percent Decrease Since July 2023 -- Data Talk

Dow Jones
·
Oct 30, 2025

Apellis falls -19.3%

TIPRANKS
·
Oct 30, 2025